Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 1967-1973

  Mesia R ^a   Rivera, F ^b   Kawecki, A ^c   Rottey, S ^d   Hitt, R ^e   Kienzer, H ^f   Cupissol, D ^g   De raucourt, D ^h   Benasso, M ⁱ   Koralewski, P ^j   Delord, J P ^k   Bokemeyer, C ^l   Curran, D ^m   Gross, A ⁿ   Vermorken, J B ^o  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f KAISER FRANZ JOSEF HOSPITAL   (Austria)

^g CENTRE VAL D AURELLE   (France)

^h François Baclesse Institute   (France)

ⁱ San Paolo Hospital   (Italy)

^j Rydygier Memorial Hospital   (Poland)

^k INSTITUT CLAUDIUS REGAUD   (France)

^l UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^m Statistics   (Ireland)

ⁿ MERCK KGAA   (Germany)

^o ANTWERP UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Cetuximab; Cisplatin; Head and neck cancer; Quality of life; Recurrent and metastatic

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DYSPHAGIA; EATING DISORDER; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUALITY OF LIFE HEAD AND NECK 35; QUALITY OF LIFE QUESTIONNAIRE CORE 30; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SOCIAL INTERACTION; SPEECH DISORDER; SQUAMOUS CELL CARCINOMA; SYMPTOMATOLOGY; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77956703721     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq077     Document Type: Article

References (15)

1. Schantz SP, Harrison LB, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In DeVita VT, Hellman SA, Rosenberg SA (eds): Cancer. Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott Williams & Wilkins 2001; 797-860.
2. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
3. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177.
4. Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654.
5. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
6. Bourhis J, Rivera F, Mesia R et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2866-2872.
7. Au H-J, Karapetis CS, O'Callaghan CJ et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 2009; 27: 1822-1828.
8. Folprecht F, Nowacki M, Lang I et al. Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): a quality-of-life (QoL) analysis of the CRYSTAL trial. J Clin Oncol 2009; 27: 15s (Abstr 4076).
9. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319.
10. Curran D, Giralt J, Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25: 2191-2197.
11. Fayers PM, Aaronson NK, Bjordal K et al. EORTC QLQ-C30 Scoring Manual. Brussels, Belgium: EORTC 1999.
12. Bjordal K, de Graeff A, Fayers PM et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000; 36: 1796-1807.
13. Sherman AC, Simonton S, Adams DC et al. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Arch Otolaryngol Head Neck Surg 2000; 126: 459-467.
14. Grignon LM, Jameson MJ, Karnell LH et al. General health measures and long-term survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2007; 133: 471-476.
15. Karvonen-Gutierrez CA, Ronis DL, Fowler KE et al. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol 2008; 26: 2754-2760.